S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.00 (-2.22%)
AAPL   164.68 (-1.41%)
MSFT   398.93 (-1.32%)
META   479.10 (-4.52%)
GOOGL   153.30 (-1.74%)
AMZN   173.78 (-3.04%)
TSLA   147.07 (-1.91%)
NVDA   771.38 (-8.90%)
AMD   146.09 (-5.80%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.07 (+0.08%)
MU   106.22 (-5.10%)
GE   148.18 (-3.11%)
CGC   8.00 (+2.17%)
DIS   112.10 (-0.29%)
AMC   3.19 (+9.25%)
PFE   25.91 (+2.05%)
PYPL   61.83 (-0.43%)
XOM   119.74 (+1.03%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.00 (-2.22%)
AAPL   164.68 (-1.41%)
MSFT   398.93 (-1.32%)
META   479.10 (-4.52%)
GOOGL   153.30 (-1.74%)
AMZN   173.78 (-3.04%)
TSLA   147.07 (-1.91%)
NVDA   771.38 (-8.90%)
AMD   146.09 (-5.80%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.07 (+0.08%)
MU   106.22 (-5.10%)
GE   148.18 (-3.11%)
CGC   8.00 (+2.17%)
DIS   112.10 (-0.29%)
AMC   3.19 (+9.25%)
PFE   25.91 (+2.05%)
PYPL   61.83 (-0.43%)
XOM   119.74 (+1.03%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.00 (-2.22%)
AAPL   164.68 (-1.41%)
MSFT   398.93 (-1.32%)
META   479.10 (-4.52%)
GOOGL   153.30 (-1.74%)
AMZN   173.78 (-3.04%)
TSLA   147.07 (-1.91%)
NVDA   771.38 (-8.90%)
AMD   146.09 (-5.80%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.07 (+0.08%)
MU   106.22 (-5.10%)
GE   148.18 (-3.11%)
CGC   8.00 (+2.17%)
DIS   112.10 (-0.29%)
AMC   3.19 (+9.25%)
PFE   25.91 (+2.05%)
PYPL   61.83 (-0.43%)
XOM   119.74 (+1.03%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.00 (-2.22%)
AAPL   164.68 (-1.41%)
MSFT   398.93 (-1.32%)
META   479.10 (-4.52%)
GOOGL   153.30 (-1.74%)
AMZN   173.78 (-3.04%)
TSLA   147.07 (-1.91%)
NVDA   771.38 (-8.90%)
AMD   146.09 (-5.80%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.07 (+0.08%)
MU   106.22 (-5.10%)
GE   148.18 (-3.11%)
CGC   8.00 (+2.17%)
DIS   112.10 (-0.29%)
AMC   3.19 (+9.25%)
PFE   25.91 (+2.05%)
PYPL   61.83 (-0.43%)
XOM   119.74 (+1.03%)
NASDAQ:GNCAQ

Genocea Biosciences (GNCAQ) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GNCAQ stock logo

About Genocea Biosciences Stock (NASDAQ:GNCAQ)

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.

GNCAQ Stock News Headlines

Genocea Bio (GNCAQ) Earnings Dates & Reports
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Genocea Biosciences Inc (GNCAQ)
GNCAQ - Genocea Biosciences, Inc.
See More Headlines
Receive GNCAQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GNCAQ
Employees
74
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.64 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
2.31
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. William D. Clark M.B.A. (Age 55)
    President, CEO & Director
    Comp: $837.42k
  • Ms. Diantha Duvall CPA (Age 52)
    M.B.A., CFO & Secretary

GNCAQ Stock Analysis - Frequently Asked Questions

How do I buy shares of Genocea Biosciences?

Shares of GNCAQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNCAQ) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners